| SOXS 1.79 4.07% | NVDA 177.19 -4.16% | ONMD 1.02 44.60% | NFLX 96.24 13.77% | JEM 0.096 3.90% | ENSC 0.6232 57.77% | BYND 0.9456 15.32% | PLUG 1.79 -6.28% | SOFI 17.76 -7.02% | NVD 7.53 8.50% | TZA 6.23 5.06% | NU 14.98 -0.53% | DUST 3.54 -3.50% | BITO 9.06 -2.78% | EOSE 5.695 -15.50% | XLF 51.43 -2.04% | BAC 49.83 -4.72% | AAL 13.07 -6.24% | MARA 8.94 5.80% | VEEA 0.5071 17.33% | SPY 685.99 -0.48% | SOXL 62.77 -3.93% | SLV 84.99 5.64% | XWEL 1.49 9.56% | QQQ 607.29 -0.32% | ONDS 10.08 -3.54% | BHAT 0.0495 -11.13% | PSKY 13.51 20.84% | INTC 45.61 0.33% | F 14.095 -2.19% | AAPL 264.18 -3.21% | XLE 55.92 1.58% | TQQQ 49.52 -1.06% | TSLA 402.51 -1.49% | HYG 80.72 -0.16% | TSDD 9.18 2.91% | TSLL 14.7 -3.10% | BATL 5.52 33.01% | RKT 18.19 2.36% | RXT 1.95 -14.47% | TLT 90.82 0.61% | TSLS 5.64 1.62% | WBD 28.17 -2.19% | PATH 10.73 0.14% | CRWV 79.56 -18.51% | IBIT 37.19 -2.80% | LQD 111.68 -0.04% | SOUN 8.6015 -4.21% | PLTR 137.19 0.92% | CPNG 19.08 1.98%

Establishment Labs Holdings Inc. (NASDAQ: ESTA) Surpasses Revenue Estimates

Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company that focuses on enhancing women's health and wellness, particularly in breast aesthetics and reconstruction. On February 24, 2026, ESTA reported its earnings, revealing a revenue of approximately $64.6 million, which surpassed the estimated $63.8 million. This achievement highlights the company's ability to exceed market expectations.

Despite reporting a quarterly loss of $0.09 per share, ESTA's performance was significantly better than the Zacks Consensus Estimate of a loss of $0.22 per share. This marks a substantial improvement from the previous year's loss of $0.98 per share, indicating a positive trend in the company's financial performance. The improvement in earnings per share suggests that ESTA is making strides in managing its expenses and improving profitability.

The company's fourth-quarter revenue of $64.6 million represents a significant increase of 45.2% compared to the same period last year. For the entire year of 2025, ESTA achieved a revenue of $211.1 million. This growth reflects the company's successful strategies in expanding its operations and capturing a larger market share in the medical technology sector.

ESTA's financial metrics reveal some challenges, such as a negative price-to-earnings (P/E) ratio of -42.77 and an earnings yield of -2.34%, indicating negative earnings. However, the company's price-to-sales ratio of 10.15 and enterprise value to sales ratio of 9.80 suggest that investors are willing to pay a premium for its sales, reflecting confidence in its future growth potential.

The company's debt-to-equity ratio is relatively low at 0.12, indicating a conservative use of debt in its capital structure. Additionally, ESTA's current ratio of 3.04 demonstrates a strong liquidity position, ensuring the company can cover its short-term liabilities. These financial metrics suggest that while ESTA faces challenges in generating positive earnings, it maintains a solid financial foundation to support its growth initiatives.

Published on: February 24, 2026